Genetic variation and its role in malignancy

International Journal of Biomedical Science

Volumn 7, Issue 3, 2011, Pages 158-171

  Talseth Palmer, Bente A ^a,b   Scott, Rodney J ^a,b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

Author keywords

DNA damage and repair; Environmental influence; Genetic variation; Malignancy

Indexed keywords

BENZENE; POLYCYCLIC AROMATIC HYDROCARBON;

BREAST CANCER; CANCER GENETICS; CANCER RISK; CARCINOGENESIS; COPY NUMBER VARIATION; DNA DAMAGE; DNA REPAIR; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTOXICITY; HUMAN; HUMAN GENOME PROJECT; NONHUMAN; REVIEW; SKIN CANCER; TUMOR GENE;

EID: 80054011620     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Review

References (239)

1. Schmith VD, Campbell DA, Sehgal S, et al. Pharmacogenetics and disease genetics of complex diseases. Cell Mol. Life Sci. 2003; 60 (8): 1636-1646.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100 (1): 57-70.
3. Eccles D, Tapper W. The influence of common polymorphisms on breast cancer. Cancer Treat Res. 2010; 155: 15-32.
4. Nevo E. Genetic variation in natural populations: patterns and theory. Theor. Popul. Biol. 1978; 13 (1): 121-177.
5. Kaneko K, Furusawa C. An evolutionary relationship between genetic variation and phenotypic fluctuation. J. Theor. Biol. 2005.
6. McKeigue PM. Mapping genes underlying ethnic differences in disease risk by linkage disequilibrium in recently admixed populations. Am. J. Hum. Genet. 1997; 60 (1): 188-196.
7. Shriver MD. Ethnic variation as a key to the biology of human dis ease. Ann. Intern. Med. 1997; 127 (5): 401-403.
8. Shriver MD, Mei R, Parra EJ, et al. Large-scale SNP analysis reveals clustered and continuous patterns of human genetic variation. Hum. Genomics. 2005; 2 (2): 81-89.
9. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet. 2001; 17 (9): 502-510.
10. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat. Rev. Genet. 2006; 7 (2): 85-97.
11. Przeworski M, Hudson RR and Di Rienzo A: Adjusting the focus on human variation. Trends Genet. 2000; 16 (7): 296-302.
12. Gregory TR, Nicol JA, Tamm H, et al. Eukaryotic genome size databases. Nucleic. Acids Res. 2007; 35 (Database issue): D332-338.
13. Vinogradov AE. Evolution of genome size: multilevel selection, mutation bias or dynamical chaos? Curr. Opin. Genet. Dev. 2004; 14 (6): 620-626.
14. Das B, Seshadri M. Genetic variability at the D1S80 minisatellite: predominance of allele 18 among some indian populations. Ann. Hum. Biol. 2004; 31 (5): 541-553.
15. Supply P, Warren RM, Banuls AL, et al. Linkage disequilibrium between minisatellite loci supports clonal evolution of Mycobacterium tuberculosis in a high tuberculosis incidence area. Mol. Microbiol. 2003; 47 (2): 529-538.
16. Tamaki K, Jeffreys AJ. Human tandem repeat sequences in forensic DNA typing. Leg. Med. (Tokyo). 2005; 7 (4): 244-250.
17. Bennett P. Demystified... microsatellites. Mol. Pathol. 2000; 53 (4): 177-183.
18. Hearne CM, Ghosh S, Todd JA. Microsatellites for linkage analysis of genetic traits. Trends Genet. 1992; 8 (8): 288-294.
19. Brookes AJ. The essence of SNPs. Gene. 1999; 234 (2): 177-186.
20. Riva A, Kohane IS. SNPper: retrieval and analysis of human SNPs. Bioinformatics. 2002; 18 (12): 1681-1685.
21. Shastry BS. SNP alleles in human disease and evolution. J. Hum. Genet. 2002; 47 (11): 561-566.
22. Sunyaev S, Ramensky V, Koch I, et al. Prediction of deleterious human alleles. Hum. Mol. Genet. 2001; 10 (6): 591-597.
23. Dhami P, Coffey AJ, Abbs S, et al. Exon array CGH: detection of copy-number changes at the resolution of individual exons in the human genome. Am. J. Hum. Genet. 2005; 76 (5): 750-762.
24. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat. Genet. 2004; 36 (9): 949-951.
25. Stankiewicz P, Lupski JR. Molecular-evolutionary mechanisms for genomic disorders. Curr. Opin. Genet. Dev. 2002; 12 (3): 312-319.
26. Wilson GM, Flibotte S, Chopra V, et al. DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. Hum. Mol. Genet. 2006; 15 (5): 743-749.
27. Sharp AJ, Locke DP, McGrath SD, et al. Segmental duplications and copy-number variation in the human genome. Am. J. Hum. Genet. 2005; 77 (1): 78-88.
28. Stefansson H, Helgason A, Thorleifsson G, et al. A common inversion under selection in Europeans. Nat. Genet. 2005; 37 (2): 129-137.
29. Tuzun E, Sharp AJ, Bailey JA, et al. Fine-scale structural variation of the human genome. Nat. Genet. 2005; 37 (7): 727-732.
30. Freeman JL, Perry GH, Feuk L, et al. Copy number variation: new insights in genome diversity. Genome Res. 2006; 16(8):949-61.
31. Smit AF. Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr. Opin. Genet. Dev. 1999; 9 (6): 657-663.
32. Druker R and Whitelaw E. Retrotransposon-derived elements in the mammalian genome: a potential source of disease. J. Inherit. Metab. Dis. 2004; 27 (3): 319-330.
33. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409 (6822): 860-921.
34. Arlt MF, Durkin SG, Ragland RL, Glover TW. Common fragile sites as targets for chromosome rearrangements. DNA Repair. (Amst). 2006; 5 (9-10): 1126-1135.
35. Richards RI. Dynamic mutations: a decade of unstable expanded repeats in human genetic disease. Hum. Mol. Genet. 2001; 10 (20): 2187-2194.
36. Sutherland GR, Baker E. The clinical significance of fragile sites on human chromosomes. Clin. Genet. 2000; 58 (3): 157-161.
37. Sprenger R, Schlagenhaufer R, Kerb R, et al. Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics. 2000; 10 (6): 557-565.
38. Maki H. Origins of spontaneous mutations: specificity and directionality of base-substitution, frameshift, and sequence-substitution mutageneses. Annu. Rev. Genet. 2002; 36: 279-303.
39. Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome. Res. 1998; 8 (12): 1229-1231.
40. Hamilton BA. Variations in abundance: genome-wide responses to genetic variation and vice versa. Genome. Biol. 2002; 3 (10): reviews 1029.
41. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor ori gin of human cancer. Nat. Rev. Genet. 2006; 7 (1): 21-33.
42. Rakyan VK, Beck S. Epigenetic variation and inheritance in mammals. Curr. Opin. Genet. Dev. 2006; 16 (6): 573-577.
43. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell. 2010; 19 (5): 698-711.
44. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116 (2): 281-297.
45. Markham AF, Coletta PL, Robinson PA, et al. Screening for cancer predisposition. Eur. J. Cancer. 1994; 30A (13): 2015-2029.
46. Tamura K, Utsunomiya J, Iwama T, et al. Mechanism of carcinogenesis in familial tumors. Int. J. Clin. Oncol. 2004; 9 (4): 232-245.
47. Vineis P. Individual susceptibility to carcinogens. Oncogene. 2004; 23 (38): 6477-6483.
48. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411 (6835): 366-374.
49. Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat. Res. 2001; 486 (2): 71-87.
50. Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. 2001; 477 (1-2): 131-153.
51. Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet. 2000; 16 (2): 69-74.
52. Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv. Clin. Chem. 2010; 51: 71-119.
53. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471 (7339): 467-472.
54. Maresca B, Schwartz JH. Sudden origins: a general mechanism of evolution based on stress protein concentration and rapid environmental change. Anat. Rec. B New Anat. 2006; 289 (1): 38-46.
55. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 1993; 362 (6422): 709-715.
56. Loeb LA. Endogenous carcinogenesis: molecular oncology into the twenty-first century--presidential address. Cancer Res. 1989; 49 (20): 5489-5496.
57. McGowan CH, Russell P. The DNA damage response: sensing and signaling. Curr. Opin. Cell Biol. 2004; 16 (6): 629-633.
58. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004; 73: 39-85.
59. Attardi LD. The role of p53-mediated apoptosis as a crucial antitumor response to genomic instability: lessons from mouse models. Mutat. Res. 2005; 569 (1-2): 145-157.
60. Ishikawa T, Zhang SS, Qin X, et al. DNA repair and cancer: lessons from mutant mouse models. Cancer Sci. 2004; 95 (2): 112-117.
61. Schmitt E, Paquet C, Beauchemin M, Bertrand R. DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J. Zhejiang Univ. Sci. B. 2007; 8 (6): 377-397.
62. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat. Res. 2005; 577 (1-2): 275-283.
63. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001; 291 (5507): 1284-1289.
64. Ataian Y, Krebs JE. Five repair pathways in one context: chromatin modification during DNA repair. Biochem. Cell Biol. 2006; 84 (4): 490-504.
65. Bassing CH, Alt FW. The cellular response to general and pro grammed DNA double strand breaks. DNA Repair. (Amst). 2004; 3 (8-9): 781-796.
66. Costa RM, Chigancas V, Galhardo Rda S, et al. The eukaryotic nucleotide excision repair pathway. Biochimie. 2003; 85 (11): 1083-1099.
67. Franco S, Alt FW, Manis JP. Pathways that suppress programmed DNA breaks from progressing to chromosomal breaks and translocations. DNA Repair. (Amst). 2006; 5 (9-10): 1030-1041.
68. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer. 2004; 4 (4): 296-307.
69. Lees-Miller SP, Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie. 2003; 85 (11): 1161-1173.
70. Mills KD, Ferguson DO, Alt FW. The role of DNA breaks in genomic instability and tumorigenesis. Immunol. Rev. 2003; 194: 77-95.
71. Nordstrand LM, Ringvoll J, Larsen E, Klungland A. Genome instability and DNA damage accumulation in gene-targeted mice. Neuroscience. 2007.
72. Schofield MJ, Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annu. Rev. Microbiol. 2003; 57: 579-608.
73. Wyman C, Ristic D, Kanaar R. Homologous recombination-mediated double-strand break repair. DNA Repair. (Amst). 2004; 3 (8-9): 827-833.
74. Peterson CL, Cote J. Cellular machineries for chromosomal DNA repair. Genes Dev. 2004; 18 (6): 602-616.
75. Rojas E, Lopez MC, Valverde M. Single cell gel electrophoresis assay: methodology and applications. J. Chromatogr. B Biomed. Sci. Appl. 1999; 722 (1-2): 225-254.
76. Nadin SB, Vargas-Roig LM, Drago G, et al. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett. 2006; 239 (1): 84-97.
77. Berwick M, Vineis P. Measuring DNA repair capacity: small steps. J. Natl. Cancer Inst. 2005; 97 (2): 84-85.
78. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev. 2005; 31 (8): 603-617.
79. Kennedy DO, Agrawal M, Shen J, et al. DNA repair capacity of lymphoblastoid cell lines from sisters discordant for breast cancer. J. Natl. Cancer Inst. 2005; 97 (2): 127-132.
80. Zijno A, Verdina A, Galati R, et al. Influence of DNA repair poly morphisms on biomarkers of genotoxic damage in peripheral lymphocytes of healthy subjects. Mutat. Res. 2006; 600 (1-2): 184-192.
81. Mohrenweiser HW. Genetic variation and exposure related risk estimation: will toxicology enter a new era? DNA repair and cancer as a paradigm. Toxicol. Pathol. 2004; 32 Suppl 1: 136-145.
82. Schmidt AL, Anderson LM. Repetitive DNA elements as mediators of genomic change in response to environmental cues. Biol. Rev. Camb. Philos. Soc. 2006; 81 (4): 531-543.
83. Cutfield WS, Hofman PL, Mitchell M, Morison IM. Could Epi genetics Play a Role in the Developmental Origins of Health and Disease? Pediatr. Res. 2007.
84. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 2007; 8 (4): 253-262.
85. Chanvaivit S, Navasumrit P, Hunsonti P, et al. Exposure assessment of benzene in Thai workers, DNA-repair capacity and influence of genetic polymorphisms. Mutat. Res. 2007; 626 (1-2): 79-87.
86. Wogan GN, Hecht SS, Felton JS, et al. Environmental and chemical carcinogenesis. Semin. Cancer Biol. 2004; 14 (6): 473-486.
87. Han J, Colditz GA, Liu JS, Hunter DJ. Genetic variation in XPD, sun exposure, and risk of skin cancer. Cancer Epidemiol. Biomarkers Prev. 2005; 14 (6): 1539-1544.
88. Terry MB, Gammon MD, Zhang FF, et al. Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol. Biomarkers. Prev. 2004; 13 (12): 2053-2058.
89. Reszka E, Wasowicz W, Gromadzinska J. Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br. J. Nutr. 2006; 96 (4): 609-619.
90. Colnot S, Niwa-Kawakita M, Hamard G, et al. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab. Invest. 2004; 84 (12): 1619-1630.
91. Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer. 1999; 86 (11 Suppl): 2575-2582.
92. Human_Genome_Project: Human Genome Program, U.S. Department of Energy, Genomics and Its Impact on Science and Society: A 2003 Primer. 2003.
93. Klose J. Genotypes and phenotypes. Electrophoresis. 1999; 20 (4-5): 643-652.
94. Bennett MD, Leitch IJ. Plant genome size research: a field in focus. Ann. Bot. (Lond). 2005; 95 (1): 1-6.
95. Griffing B, Scholl RL. Qualitative and quantitative genetic studies of Arabidopsis thaliana. Genetics. 1991; 129 (3): 605-609.
96. Latchman DS. Heat shock proteins and human disease. J. R. Coll. Physicians Lond. 1991; 25 (4): 295-299.
97. Lonai P, Orr-Urtreger A. Homeogenes in mammalian development and the evolution of the cranium and central nervous system. Faseb. J. 1990; 4 (5): 1436-1443.
98. Nagy A, Perrimon N, Sandmeyer S, Plasterk R. Tailoring the genome: the power of genetic approaches. Nat. Genet. 2003; 33 Suppl: 276-284.
99. Ross-Macdonald P. Functional analysis of the yeast genome. Funct. Integr. Genomics. 2000; 1 (2): 99-113.
100. Schaechter M. Escherichia coli and Salmonella 2000: the view from here. Microbiol. Mol. Biol. Rev. 2001; 65 (1): 119-130.
101. Lander ES. Genome-sequencing anniversary. The accelerator. Science. 2011; 331 (6020): 1024.
102. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J. Clin. Oncol. 2007; 25 (12): 1606-1620.
103. Maillet P, Chappuis PO, Khoshbeen-Boudal M, et al. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families. Cancer Genet. Cytogenet. 2006; 169 (1): 62-68.
104. Pillay VV, Menezes RG, Krishnaprasad R, et al. Biotechnology in forensic science: the revolution continues. Nepal. Med. Coll. J. 2007; 9 (1): 57-62.
105. Van Lanen SG, Shen B. Microbial genomics for the improvement of natural product discovery. Curr. Opin. Microbiol. 2006; 9 (3): 252-260.
106. Verschure PJ, Visser AE, Rots MG. Step out of the groove: epigen etic gene control systems and engineered transcription factors. Adv. Genet. 2006; 56: 163-204.
107. The_ENCODE_Project_Cosortium: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007; 447 (7146): 799-816.
108. Weinstock GM. ENCODE: more genomic empowerment. Genome. research. 2007; 17 (6): 667-668.
109. Gerstein MB, Bruce C, Rozowsky JS, et al. What is a gene, postENCODE? History and updated definition. Genome. research. 2007; 17 (6): 669-681.
110. Int._HapMap_Consortium: The International HapMap Project. Nature. 2003; 426 (6968): 789-796.
111. Int._HapMap_Consortium: A haplotype map of the human genome. Nature. 2005; 437 (7063): 1299-1320.
112. McVean G, Spencer CC, Chaix R. Perspectives on human genetic variation from the HapMap Project. PLOS Genet. 2005; 1 (4): e54.
113. Loeb LA, Springgate CF, Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 1974; 34 (9): 2311-2321.
114. Prindle MJ, Fox EJ, Loeb LA. The mutator phenotype in cancer: molecular mechanisms and targeting strategies. Curr. Drug Targets. 2010; 11 (10): 1296-1303.
115. Coates PJ, Lorimore SA, Wright EG. Cell and tissue responses to genotoxic stress. J. Pathol. 2005; 205 (2): 221-235.
116. Kolodner RD, Putnam CD, Myung K. Maintenance of genome stabil ity in Saccharomyces cerevisiae. Science. 2002; 297 (5581): 552-557.
117. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science. 2002; 297 (5581): 565-569.
118. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science. 2002; 297 (5581): 547-551.
119. Hasler J, Strub K. Alu elements as regulators of gene expression. Nucleic. Acids Res. 2006; 34 (19): 5491-5497.
120. Matsutani S. Links between repeated sequences. J. Biomed. Biotechnol. 2006; 2006 (1): 13569.
121. Zuckerkandl E, Cavalli G. Combinatorial epigenetics, "junk DNA", and the evolution of complex organisms. Gene. 2007; 390 (1-2): 232-242.
122. Armour JA. Tandemly repeated DNA: why should anyone care? Mutat. Res. 2006; 598 (1-2): 6-14.
123. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998; 396 (6712): 643-649.
124. Alvarez S, Cigudosa JC. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel. Hematol. Oncol. 2005; 23 (1): 18-25.
125. Pettus JA, Cowley BC, Maxwell T, et al. Multiple abnormalities detected by dye reversal genomic microarrays in prostate cancer: a much greater sensitivity than conventional cytogenetics. Cancer Genet. Cytogenet. 2004; 154 (2): 110-118.
126. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 2003; 138 (10): 819-830.
127. Deininger PL, Batzer MA. Alu repeats and human disease. Mol. Genet. Metab. 1999; 67 (3): 183-193.
128. Economou-Pachnis A, Tsichlis PN. Insertion of an Alu SINE in the human homologue of the Mlvi-2 locus. Nucleic. Acids Res. 1985; 13 (23): 8379-8387.
129. Miki Y, Katagiri T, Kasumi F, et al. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat. Genet. 1996; 13 (2): 245-247.
130. Rowe SM, Coughlan SJ, McKenna NJ, et al. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res. 1995; 55 (13): 2743-2745.
131. Varon R, Gooding R, Steglich C, et al. Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. Nat. Genet. 2003; 35 (2): 185-189.
132. Hung RJ, Boffetta P, Brennan P, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int. J. Cancer. 2004; 110 (4): 598-604.
133. Lee KM, Park SK, Kim SU, et al. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Lett. 2003; 196 (2): 179-186.
134. Shin JH, Ku JL, Shin KH, et al. Glutathione S-transferase M1 associated with cancer occurrence in Korean HNPCC families carrying the hMLH1/hMSH2 mutation. Oncol. Rep. 2003; 10 (2): 483-486.
135. Sorensen M, Autrup H, Tjonneland A, et al. Glutathione S-transferase T1 null-genotype is associated with an increased risk of lung cancer. Int. J. Cancer. 2004; 110 (2): 219-224.
136. Spurdle AB, Webb PM, Purdie DM, et al. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis. 2001; 22 (1): 67-72.
137. Arlt MF, Casper AM, Glover TW. Common fragile sites. Cytogenet. Genome. Res. 2003; 100 (1-4): 92-100.
138. Balsara BR, Pei J, De Rienzo A, et al. Human hepatocellular car cinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer. 2001; 30 (3): 245-253.
139. Hansen LL, Yilmaz M, Overgaard J, et al. Allelic loss of 16q23.224.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res. 1998; 58 (10): 2166-2169.
140. Kovacs G, Erlandsson R, Boldog F, et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc. Natl. Acad. Sci. USA. 1988; 85 (5): 1571-1575.
141. Maitra A, Wistuba, II, Gibbons D, et al. Allelic losses at chromosome 3p are seen in human papilloma virus 16 associated transitional cell carcinoma of the cervix. Gynecol. Oncol. 1999; 74 (3): 361-368.
142. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature. 1987; 329 (6138): 451-454.
143. Paris PL, Witte JS, Kupelian PA, et al. Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer suscepti bility locus. Cancer Res. 2000; 60 (13): 3645-3649.
144. Rader JS, Kamarasova T, Huettner PC, et al. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene. 1996; 13 (12): 2737-2741.
145. Wang N, Perkins KL. Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. Cancer Genet Cytogenet. 1984; 11 (4): 479-481.
146. Yokoyama S, Yamakawa K, Tsuchiya E, et al. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 1992; 52 (4): 873-877.
147. Smeets DF, Scheres JM, Hustinx TW. The most common fragile site in man is 3p14. Hum. Genet. 1986; 72 (3): 215-220.
148. Sutherland GR, Richards RI. The molecular basis of fragile sites in human chromosomes. Curr. Opin. Genet Dev. 1995; 5 (3): 323-327.
149. Ramos D, Aldaz CM. WWOX, a chromosomal fragile site gene and its role in cancer. Adv. Exp. Med. Biol. 2006; 587: 149-159.
150. Barros P, Blanco MG, Boan F, Gomez-Marquez J. Heteroduplex analysis of minisatellite variability. Electrophoresis. 2005; 26 (22): 4304-4309.
151. Krontiris TG, DiMartino NA, Colb M, Parkinson DR. Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature. 1985; 313 (6001): 369-374.
152. Langdon JA, Armour JA. Evolution and population genetics of the H-ras minisatellite and cancer predisposition. Hum. Mol. Genet. 2003; 12 (8): 891-900.
153. Ponder BA. Cancer genetics. Nature. 2001; 411 (6835): 336-341.
154. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 2002; 31 (1): 33-36.
155. Bell J. The new genetics in clinical practice. BMJ. 1998; 316 (7131): 618-620.
156. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N. Engl. J. Med. 2000; 343 (2): 141-144.
157. Beroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic. Acids Res. 1996; 24 (1): 121-124.
158. Kim CJ, Lee JH, Song JW, et al. Chk1 frameshift mutation in spo radic and hereditary non-polyposis colorectal cancers with microsatellite instability. Eur. J. Surg. Oncol. 2007; 33 (5): 580-585.
159. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology. 1997; 113 (4): 1146-1158.
160. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378 (6559): 789-792.
161. Nuzzo V, Tauchmanova L, Falchetti A, et al. MEN1 family with a novel frameshift mutation. J. Endocrinol. Invest. 2006; 29 (5): 450-456.
162. Fijneman RJ. Genetic predisposition to sporadic cancer: how to han dle major effects of minor genes? Cell Oncol. 2005; 27 (5-6): 281-292.
163. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119 (5): 591-602.
164. Braude I, Vukovic B, Prasad M, et al. Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia. BMC Genomics. 2006; 7: 138.
165. Davies SM, Bhatia S, Ross JA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002; 100 (1): 67-71.
166. DeMichele A, Martin AM, Mick R, et al. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003; 63 (22): 8051-8056.
167. Frank B, Bermejo JL, Hemminki K, et al. Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk. Carcinogenesis. 2007.
168. Heinimann K, Scott RJ, Chappuis P, et al. N-acetyltransferase 2 influences cancer prevalence in hMLH1/hMSH2 mutation carriers. Cancer Res. 1999; 59 (13): 3038-3040.
169. Jones JS, Chi X, Gu X, et al. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin. Cancer Res. 2004; 10 (17): 5845-5849.
170. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004; 4 (1): 66-72.
171. Sotamaa K, Liyanarachchi S, Mecklin JP, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin. Cancer Res. 2005; 11 (19 Pt 1): 6840-6844.
172. Sun T, Gao Y, Tan W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat. Genet. 2007; 39 (5): 605-613.
173. Talseth-Palmer BA, Brenne IS, Ashton KA, et al. Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in lynch syndrome. J. Med. Genet. 2011; 48 (4): 279-284.
174. Wijnen JT, Brohet RM, van Eijk R, et al. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology. 2009; 136 (1): 131-137.
175. Govan VA, Carrara HR, Sachs JA, et al. Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J. Carcinog. 2003; 2 (1): 3.
176. Hoffmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am. J. Transplant. 2002; 2 (6): 560-567.
177. Inserra P, Abrahamsen M, Papenfuss M, Giuliano AR. Ethnic varia tion of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int. J. STD AIDS. 2003; 14 (12): 800-804.
178. Lohmueller KE, Mauney MM, Reich D, Braverman JM. Variants associated with common disease are not unusually differentiated in frequency across populations. Am. J. Hum. Genet. 2006; 78 (1): 130-136.
179. Martin ER, Lai EH, Gilbert JR, et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am. J. Hum. Genet. 2000; 67 (2): 383-394.
180. Pritchard JK, Cox NJ. The allelic architecture of human disease genes: common disease-common variant...or not? Hum. Mol. Genet. 2002; 11 (20): 2417-2423.
181. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996; 273 (5281): 1516-1517.
182. Suh Y, Vijg J. SNP discovery in associating genetic variation with human disease phenotypes. Mutat. Res. 2005; 573 (1-2): 41-53.
183. Terwilliger JD, Weiss KM. Linkage disequilibrium mapping of complex disease: fantasy or reality? Curr. Opin. Biotechnol. 1998; 9 (6): 578-594.
184. Wright AF, Hastie ND. Complex genetic diseases: controversy over the Croesus code. Genome. Biol. 2001; 2 (8): COMMENT 2007.
185. Kristinsson SY, Thorolfsdottir ET, Talseth B, et al. MODY in Iceland is associated with mutations in HNF-1alpha and a novel mutation in NeuroD1. Diabetologia. 2001; 44 (11): 2098-2103.
186. Garcia-Closas M, Malats N, Real FX, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLOS Genet. 2007; 3 (2): e29.
187. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat. Rev. Cancer. 2004; 4 (11): 850-860.
188. Pharoah PD, Tyrer J, Dunning AM, et al. Association between Common Variation in 120 Candidate Genes and Breast Cancer Risk. PLOS Genet. 2007; 3 (3): e42.
189. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum. Mol. Genet. 2009; 18 (R2): R163-168.
190. Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 2007; 39 (8): 984-988.
191. Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001; 61 (16): 6042-6045.
192. Zanke BW, Greenwood CM, Rangrej J, et al. Genome-wide associa tion scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 2007; 39 (8): 989-994.
193. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nature reviews. Genetics. 2009; 10 (4): 241-251.
194. Roberts R, Wells GA, Stewart AF, et al. The genome-wide association study--a new era for common polygenic disorders. J. Cardiovasc. Transl. Res. 2010; 3 (3): 173-182.
195. Stadler ZK, Gallagher DJ, Thom P, Offit K. Genome-wide associa tion studies of cancer: principles and potential utility. Oncology. (Williston Park). 2010; 24 (7): 629-637.
196. Kuiper RP, Ligtenberg MJ, Hoogerbrugge N, Geurts van Kessel A. Germline copy number variation and cancer risk. Curr. Opin. Genet. Dev. 2010; 20 (3): 282-289.
197. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human dis ease. Science. 2008; 322 (5903): 881-888.
198. Johnson AD, O'Donnell CJ. An open access database of genomewide association results. BMC Med. Genet. 2009; 10: 6.
199. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007.
200. Stadler ZK, Vijai J, Thom P, et al. Genome-wide association studies of cancer predisposition. Hematology/oncology clinics. of North America. 2010; 24 (5): 973-996.
201. Yoshida T, Ono H, Kuchiba A, et al. Genome-wide germline analyses on cancer susceptibility and GeMDBJ database: Gastric cancer as an example. Cancer Sci. 2010; 101 (7): 1582-1589.
202. Huo D, Olopade OI. Interpretation of genome-wide association study results. Oncology. 2010; 24 (7): 643-646.
203. Speicher MR, Geigl JB, Tomlinson IP. Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk. The lancet oncology. 2010; 11 (9): 890-898.
204. Cho EK, Tchinda J, Freeman JL, et al. Array-based comparative genomic hybridization and copy number variation in cancer research. Cytogenet. Genome. Res. 2006; 115 (3-4): 262-272.
205. Mantripragada KK, Buckley PG, de Stahl TD, Dumanski JP. Genomic microarrays in the spotlight. Trends Genet. 2004; 20 (2): 87-94.
206. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 1998; 20 (2): 207-211.
207. Pollack JR, Perou CM, Alizadeh AA, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet. 1999; 23 (1): 41-46.
208. Peiffer DA, Le JM, Steemers FJ, et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome. Res. 2006; 16 (9): 1136-1148.
209. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006; 444 (7118): 444-454.
210. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006; 444 (7118): 444-454.
211. Shlien A, Tabori U, Marshall CR, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc. Natl. Acad. Sci. USA. 2008; 105 (32): 11264-11269.
212. Dear PH. Copy-number variation: the end of the human genome? Trends Biotechnol. 2009; 27 (8): 448-454.
213. Chen Y, Chen C. DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a review. Head Neck. 2008; 30 (10): 1361-1383.
214. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463 (7283): 899-905.
215. Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer-the application of DNA methylation markers. J. Appl. Genet. 2006; 47 (4): 365-375.
216. Esteller M: Cancer epigenomics: DNA methylomes and histonemodification maps. Nat. Rev. Genet. 2007; 8 (4): 286-298.
217. Toyota M, Suzuki H. Epigenetic drivers of genetic alterations. Adv. Genet. 2010; 70: 309-323.
218. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA. 2006; 103 (24): 9136-9141.
219. Ramsingh G, Koboldt DC, Trissal M, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010; 116 (24): 5316-5326.
220. Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron. 2010; 3 (1): 137-147.
221. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nature reviews. Cancer. 2010; 10 (6): 389-402.
222. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl. Acad. Sci. USA. 2010; 107 (28): 12629-12633.
223. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330 (6001): 228-231.
224. Bodmer W, Tomlinson I. Rare genetic variants and the risk of cancer. Curr. Opin. Genet. Dev. 2010; 20 (3): 262-267.
225. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 2010; 11 (6): 415-425.
226. Lander ES. Initial impact of the sequencing of the human genome. Nature. 2011; 470 (7333): 187-197.
227. Risch A, Plass C. Lung cancer epigenetics and genetics. International journal of cancer. Journal international du cancer. 2008; 123 (1): 1-7.
228. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nature genetics. 2003; 33 Suppl: 238-244.
229. Gusella JF, MacDonald ME. Huntington's disease. Semin. Cell Biol. 1995; 6 (1): 21-28.
230. Tsui LC. The spectrum of cystic fibrosis mutations. Trends Genet. 1992; 8 (11): 392-398.
231. Seddon JM, Francis PJ, George S, et al. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA. 2007; 297 (16): 1793-1800.
232. The_Welcome_Trust_Case_Control_Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447 (7145): 661-678.
233. Tomlinson IP, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 2008; 40 (5): 623-630.
234. Rebbeck TR, Martinez ME, Sellers TA, et al. Genetic variation and cancer: improving the environment for publication of association studies. Cancer Epidemiol. Biomarkers Prev. 2004; 13 (12): 1985-1986.
235. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 2005; 91 (3): 249-258.
236. Blomhoff A, Olsson M, Johansson S, et al. Linkage disequilibrium and haplotype blocks in the MHC vary in an HLA haplotype specific manner assessed mainly by DRB1(*)03 and DRB1(*)04 haplotypes. Genes Immun. 2006; 7 (2): 130-140.
237. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002; 296 (5576): 2225-2229.
238. Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science. 2001; 294 (5547): 1719-1723.
239. Voidonikolas G, Kreml SS, Chen C, et al. Basic principles and tech nologies for deciphering the genetic map of cancer. World journal of surgery. 2009; 33 (4): 615-629.